Mark Smith, Finch Therapeutics CEO

FDA slaps hold on Finch's mi­cro­bio­me C. dif­fi­cile treat­ment, as biotech blames Covid-19 and old man­u­fac­tur­er

Drug­mak­ers work­ing on treat­ments for C. dif­fi­cile in­fec­tions are hav­ing a bad week.

Just one day af­ter Pfiz­er re­port­ed its C. dif­fi­cile vac­cine can­di­date did not hit the pri­ma­ry end­point in a Phase III study, Finch Ther­a­peu­tics is find­ing it­self in a sim­i­lar po­si­tion. The biotech said Tues­day its mi­cro­bio­me treat­ment for the in­fec­tion was placed on clin­i­cal hold by the FDA last week, with reg­u­la­tors seek­ing more in­fo on Finch’s screen­ing pro­to­cols.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.